Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Context Therapeutics stock

Learn how to easily invest in Context Therapeutics stock.

Context Therapeutics is a biotechnology business based in the US. Context Therapeutics shares (CNTX) are listed on the NASDAQ and all prices are listed in US Dollars.

How to buy Context Therapeutics stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – CNTX. It's that simple.

Best for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Promoted for easy user experience


  • Commission-free trading
  • Commission-free crypto
  • No minimum account balance



  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.

Context Therapeutics stock price (NASDAQ: CNTX)

Use our graph to track the performance of CNTX stocks over time.

Context Therapeutics shares at a glance

Information last updated 2023-01-22.
Latest market close$0.73
52-week range$0.60 - $2.79
50-day moving average $0.96
200-day moving average $1.52
Wall St. target priceN/A
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-1.93

Buy Context Therapeutics stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
Stocks, Options, ETFs, Cryptocurrency
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Stocks, ETFs, Cryptocurrency, Alternatives
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
Winner of Finder’s Best Overall Stock Broker award.

Compare up to 4 providers

*Signup bonus information updated weekly.

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Context Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Context Therapeutics price performance over time

Historical closes compared with the close of $0.73 from 2023-01-25

1 week (2023-01-20) 5.19%
1 month (2022-12-27) 9.94%
3 months (2022-10-27) -45.11%
6 months (2022-07-27) -62.18%
1 year (2022-01-27) -62.56%
2 years (2021-01-27) -99.62%
3 years (2020-01-24) 330
5 years (2018-01-23) N/A

Context Therapeutics financials

Gross profit TTM $0
Return on assets TTM -39.72%
Return on equity TTM -80.2%
Profit margin 0%
Book value $2.39
Market capitalisation $11.1 million

TTM: trailing 12 months

Context Therapeutics share dividends

We're not expecting Context Therapeutics to pay a dividend over the next 12 months.

Context Therapeutics overview

Context Therapeutics Inc. , a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc.

Frequently asked questions

What percentage of Context Therapeutics is owned by insiders or institutions?
Currently 5.821% of Context Therapeutics shares are held by insiders and 29.477% by institutions.
When does the fiscal year end for Context Therapeutics?
Context Therapeutics's fiscal year ends in December.
Where is Context Therapeutics based?
Context Therapeutics's address is: 2001 Market Street, Philadelphia, PA, United States, 19103
What is Context Therapeutics's ISIN number?
Context Therapeutics's international securities identification number is: US21077P1084

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site